Drug-eluting balloons could reduce intimal hyperplasia detected by OCT in intmerventions with conventional stents. 30 patients were randomized into 3 groups: 10 patients received conventional stents, 10 patients received a drug-eluting balloon prior to the conventional stent, and 10 patients receive a drug-eluting balloon after the conventional stent. We performed angiographic and OCT follow-up at 6 months. There were no angiographic differences after 6 months or clinical differences (death, myocardial infarction, revascularization) after 12 months. The OCT found a lower hyperplasia in patients receiving the drug-eluting balloon, but there were no differences between its use before or after stenting.
Conclusion: In simple de novo coronary lesions treated with BMS, the drug-eluting balloon significantly reduces intimal hyperplasia after 6 months as assessed by OCT The use of the drug-eluting balloon before or after stent implantation had similar efficacy.
francesco_burzotta_europcr
Francesco Burzotta
2013-05-23
Original title: IN-PACT CORO Trial: INtimalhyPerplasiaevAluated by OCT in de novo COROnary lesions treated by drug-eluting balloon and BMS – Final results.